Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases
| Autor: | Peter B. Vermeulen, T. Peter Kingham, Diederik J. Höppener, Pieter M. H. Nierop, Bas Groot Koerkamp, Cornelis Verhoef, Boris Galjart, Jinru Shia, Eric P. van der Stok, Michael I. D’Angelica, Vinod P. Balachandran, William R. Jarnagin, Florian E. Buisman, Robert R. J. Coebergh van den Braak, John M. Creasy, Eran Sadot, Dirk J. Grünhagen |
|---|---|
| Přispěvatelé: | Surgery |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Cancer Research medicine.medical_specialty Colorectal cancer medicine.medical_treatment Gastroenterology 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Hepatectomy Humans Chemotherapy Aged Retrospective Studies Hematology business.industry Liver Neoplasms Hazard ratio Cancer Histopathological growth pattern General Medicine Middle Aged Prognosis medicine.disease Survival Rate Colorectal liver metastases 030104 developmental biology Oncology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Biomarker (medicine) Female Human medicine Colorectal Neoplasms business Adjuvant Follow-Up Studies Research Paper |
| Zdroj: | Clinical and experimental metastasis Clinical and Experimental Metastasis, 37(5), 593-605. Springer Netherlands Clinical & Experimental Metastasis |
| ISSN: | 0262-0898 |
| Popis: | Adjuvant systemic chemotherapy (CTx) is widely administered in patients with colorectal liver metastases (CRLM). Histopathological growth patterns (HGPs) are an independent prognostic factor for survival after complete resection. This study evaluates whether HGPs can predict the effectiveness of adjuvant CTx in patients with resected CRLM. Two main types of HGPs can be distinguished; the desmoplastic type and the non-desmoplastic type. Uni- and multivariable analyses for overall survival (OS) and disease-free survival (DFS) were performed, in both patients treated with and without preoperative chemotherapy. A total of 1236 patients from two tertiary centers (Memorial Sloan Kettering Cancer Center, New York, USA; Erasmus MC Cancer Institute, Rotterdam, The Netherlands) were included (period 2000–2016). A total of 656 patients (53.1%) patients received preoperative chemotherapy. Adjuvant CTx was only associated with a superior OS in non-desmoplastic patients that had not been pretreated (adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.37–0.73, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink